Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment

NCT07059910 | Not Yet Recruiting FDA Drug

• 1 other identifier: ITP and thyroid disorders
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment

Conditions

Immune Thrombocytopenic Purpura; Thyroid Disorders

Outcome Measures

Primary Outcomes (2)

• Assess the frequency of thyroid disorders in patients with IT

  Screening of thyroid disorders in patients with ITP

  Assess the frequency of thyroid disorders in patients with IT

• Evaluate the treatment of thyroid disorders in improvement in platelets count.

  Evaluate if patients have managed according to thyroid disorders, will this affect in their response to ITP management

  Evaluate the treatment of thyroid disorders in improvement in platelets count.

Study Arms (1)

Patients known ITP

Patients known ITP either newly diagnosed, chronic, refractory Age 18 yrs and above Patients with thyrodiectomy will not be in our study

Diagnostic Test: Search for thyroid disorders; Diagnostic Test: Laboratory test; Drug: Steroid and eltrombopage

Interventions

Search for thyroid disorders DIAGNOSTIC_TEST

TSH , FT3 , FT4

Also known as: Laboratory test

Patients known ITP

Laboratory test DIAGNOSTIC_TEST

Search for anti thyroid antibodies

Patients known ITP

Steroid and eltrombopage DRUG

See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?

Also known as: Drugs used in ITP

Patients known ITP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

prospective cross sectional study

You may qualify if:

• ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.
• refractory ITP patients.

You may not qualify if:

• patients with history of thyroidectomy
• patients with history of drug induced ITP
• patients with history of HCV, HBV and HIV infection.
• Patients who refuse to contribute in this study.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic; Thyroid Diseases

Interventions

Clinical Laboratory Techniques; Steroids; Inosine Triphosphate

Condition Hierarchy (Ancestors)

Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombotic Microangiopathies; Thrombocytopenia; Blood Platelet Disorders; Cytopenia; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Fused-Ring Compounds; Polycyclic Compounds; Inosine Nucleotides; Purine Nucleotides; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nucleotides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleotides

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assiut

Study Record Dates

• First Submitted: June 10, 2025
• First Posted: July 11, 2025
• Study Start: July 1, 2025
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): August 15, 2026
• Last Updated: July 17, 2025

Record last verified: 2025-07